Lisbeth Barkholt
Overview
Explore the profile of Lisbeth Barkholt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barkholt L, Voltz-Girolt C, Raine J, Salmonson T, Schussler-Lenz M
Nat Rev Drug Discov
. 2018 Dec;
18(1):8-9.
PMID: 30498203
No abstract available.
2.
Omazic B, Remberger M, Barkholt L, Soderdahl G, Potacova Z, Wersall P, et al.
Biol Blood Marrow Transplant
. 2016 Jan;
22(4):676-681.
PMID: 26740375
We wanted to determine whether allogeneic hematopoietic stem cell transplantation (HSCT) may result in long-term survival in patients with solid cancer. HSCT was performed in 61 patients with solid cancer:...
3.
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, et al.
Cytotherapy
. 2013 Apr;
15(7):753-9.
PMID: 23602595
In the past decade, the therapeutic value of mesenchymal stromal cells (MSCs) has been studied in various indications, thereby taking advantage of their immunosuppressive properties. Easy procurement from bone marrow,...
4.
Conrad R, Remberger M, Cederlund K, Barkholt L
Immunotherapy
. 2011 Mar;
3(3):443-51.
PMID: 21395385
Aims: Risk factors for disease relapse are remaining tumor or leukemic cells or mixed chimerism (MC) following allogeneic hematopoietic stem cell transplantation. Donor lymphocyte infusion (DLI) after stem cell transplantation...
5.
Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, et al.
Immunotherapy
. 2010 Jul;
1(5):753-64.
PMID: 20636021
The chimeric state after allogeneic hematopoietic stem cell transplantation provides a platform for adoptive immunotherapy using donor-derived immune cells. The major risk with donor lymphocyte infusions (DLIs) is the development...
6.
Barkholt L, Bregni M
Immunotherapy
. 2010 Jul;
1(3):483-93.
PMID: 20635964
Explorative knowledge of cellular and molecular mechanisms of immune function and regulation has provided optimism in developing cancer immunotherapy. However, three decades of experimental and clinical investigations to offer powerful...
7.
Aglietta M, Barkholt L, Carnevale Schianca F, Caravelli D, Omazic B, Minotto C, et al.
Biol Blood Marrow Transplant
. 2009 Feb;
15(3):326-35.
PMID: 19203723
Reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (HCT) allowed the existence of an allogeneic cell-mediated antitumor effect in metastatic colorectal cancer (mCRC) to be explored. We report...
8.
Importance of CsA drug monitoring in SCT recipients to minimize GVHD and maximize graft vs. leukemia
Barkholt L
Pediatr Transplant
. 2008 Nov;
13(4):400-3.
PMID: 18992059
No abstract available.
9.
Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella A, et al.
Nat Clin Pract Oncol
. 2008 Apr;
5(5):256-67.
PMID: 18398414
Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an...
10.
Conrad R, Remberger M, Cederlund K, Ringden O, Barkholt L
Haematologica
. 2008 Feb;
93(2):265-72.
PMID: 18245651
Background: Following different types of conditioning, allogeneic hematopoietic stem cell transplantation produces a graft-versus-tumor effect in patients with solid tumors. We performed a non-randomized study comparing low intensity conditioning with...